Tolerability of ramipril 10 mg/day in high-risk cardiovascular Chinese patients

Clinical Drug Investigation

Volumn 22, Issue 11, 2002, Pages 771-781

  Wu, Ning ^a   Ren Zhu, Jun ^a   An Chen, Kan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIGOXIN; DIURETIC AGENT; HYPERGLYCEMIC AGENT; NITRATE; RAMIPRIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHINESE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG TOLERABILITY; EDEMA; EPISTAXIS; ESOPHAGUS DISEASE; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPOTENSION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SHOCK; STOMACH DISEASE; THORAX DISEASE; VERTIGO;

EID: 0036440311     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222110-00005     Document Type: Article

References (13)

1. Tao SQ, Zhou BF. General comment on prevention of cardiovascular diseases. In: Tao SQ, Wu YF,editors. Knowledge on Cardiovascular Diseases for Medical Personnel. Beijing: China Friendship Publishing House, 2000: 3-19
2. Wu YK, Lu CQ, Gao RC, et al. Nation-wide hypertension screening in China during 1979-1980.Chin Med J (Engl) 1982 Feb; 95(2): 101-8
3. Wu XG. Change of incidence and tendency of high blood pressure in China. Chin J Hypertens 1995; 3 (Suppl): 7-13
4. Keys A. Seven countries: A Multivariate Analysis of Health and Coronary Heart Disease. Harvard University Press, Cambridge, MA, 1980
5. Wood D, DeBacker G, Faegerman O, et al. Task force report. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434-503
6. Kaplan NM, Rose BD. Treatment of hypertension in diabetes mellitus: Guidelines based on current evidence. Ann Intern Med. 2001;135 (12): 1079-83
7. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000 Jan 20; 342 (3): 145-54
8. Ruggenenti P, Perna A, Gherardi G, et al., Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-64
9. Kaplan NM. The CARE Study: A postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin Ther. 1996; 18(4): 658-70
10. Singh NP, Uppal M, Anuradha S, et al. Agarwal Angiotensin converting enzyme inhibitors and cough: A north Indian study. J Assoc Physicians India 1998 May; 46 (5): 448-51
11. Li YX, Song ZhY, Liu SQ. Side effects of ACE inhibitors-Analysis of 102 cases. Chin Pharm 2001 May 15; 12 (5): 298-9
12. Ding PYA, Hu OYP, Pool PE, et al. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? J Hum Hypertens 2000; 14: 163-70
13. Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD Genotype. J Am Coll Cardiol 2001; 37: 1808-12